InspireMD Reports Q2 2026 Financial Results with Revenue Decline and Increased Net Loss

InspireMD, Inc. reported its financial results for the second quarter of 2026, revealing a revenue of $1.77 million, a slight decrease of 0.4% from $1.78 million in the same period last year. For the first half of 2026, the company achieved revenues of $5.17 million, marking a significant increase of 56.3% compared to $3.31 million in the first half of 2025. The growth in revenue was primarily driven by direct sales of the CGuard Prime product in the U.S. and continued international sales, although it was partially offset by $734,000 in credits issued due to a voluntary recall of the CGuard Prime delivery system.

The company reported a net loss of $14.32 million for the second quarter, an increase of 8.9% from a loss of $13.15 million in the same quarter of 2025. For the first half of 2026, the net loss was $28.01 million, up 15.2% from $24.32 million in the prior year. The increase in losses was attributed to a decline in gross profit, which turned into a loss of $774,000 for the second quarter, compared to a profit of $313,000 in the same period last year. This was largely due to the impact of the recall and associated inventory impairment costs.

In terms of operational developments, InspireMD has been focusing on its CGuard product line, which includes the CGuard Carotid Embolic Prevention System and the CGuard Prime Carotid Stent System. The company has received CE Mark recertification for CGuard EPS and is pursuing FDA approval for the same product. However, in May 2026, InspireMD announced a voluntary recall of the CGuard Prime delivery system after it failed to meet performance expectations during a controlled launch. The recall has led to a significant reduction in U.S. revenues, which were reported as negative for the second quarter due to the credits issued to customers.

As of June 30, 2026, InspireMD's total assets were $44.64 million, down from $69.40 million at the end of 2025. The company had cash and cash equivalents of $15.15 million, an increase from $8.94 million at the end of the previous year, while marketable securities decreased significantly from $45.27 million to $15.27 million. The company’s total liabilities also decreased to $13.13 million from $14.20 million, reflecting a reduction in current liabilities. InspireMD's accumulated deficit reached $330.31 million, raising concerns about its ability to continue as a going concern without additional capital.

Looking ahead, InspireMD plans to continue the commercialization of its products and is exploring options for raising capital through equity sales, debt, or strategic partnerships. However, the company faces substantial doubt regarding its ability to fund operations for at least the next 12 months, given its history of losses and negative cash flows. The management has initiated a workforce reduction initiative aimed at improving operational efficiency and reducing costs, which is expected to yield annualized savings of approximately $9 million. The company is also navigating challenges related to ongoing geopolitical tensions in Israel, where its manufacturing facility is located, which could further impact its operations and financial performance.